文献库 文献相关信息

题目:
[Clinical guidelines for diagnosing, treatment and monitoring patients with bladder cancer--Croatian Oncology Society and Croatian Urology Society, Croatian Medical Association].
作者:
Gamulin(Marija),Ruzić(Ira Pavlović),Grgić(Mislav),Jazvić(Marijana),Solarić(Mladen),Zahirović(Dag),Zorica(Robert),Omrcen(Tomislav),Petković(Marija),Matić(Mate),Fuckar(Zeljko),Ruzić(Boris),Pasini(Josip),Situm(Marijan),Dordević(Gordana),Miletić(Damir),Tadić(Tade),Kastelan(Zeljko),Librenjak(Davor),Gilja(Ivan),Vilović(Katarina),Kruslin(Bozo),Kuvezdić(Hrvoje),
状态:
发布时间2014-02-04 , 更新时间 2014-02-04
期刊:
Lijec Vjesn
摘要:
Urothelial cancer is the most common bladder cancer. Hematuria is the most common presenting symptom in patients with bladder cancer. The most common diagnostics of bladder cancer is performed by transurethral resection of bladder after which pathohistological diagnosis is set. It is necessary to determine whether the cancer penetrated in muscle layer (muscle-invasive cancer) or not (muscle-noninvasive cancer). Decision on therapeutic modality depends on the clinical stage of disease and on prognostic and risk factors. For muscle non-invasive bladder cancer transurethral resection is preferred with or without intravesical instillation of Bacillus Calmette-Guérin (BCG). For invasive cancer the method of choice is radical cystectomy. Radiotherapy is used in radical and palliative purposes. Metastatic disease is most frequently treated by chemotherapy metotrexate/vinblastine/doxorubicine/cisplatin (MVAC) or gemcitabine/cisplatin (GC). The purpose of this article is to present clinical recommendations to set standards of procedures and criteria in diagnostics, treatment and follow up of patients with bladder cancer in the Republic of Croatia.
语言:
hrv
DOI:

联系方式

山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼

电话: 0531-88819269

E-mail: product@genelibs.com

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。